Economic Benefit of the HyperQ(TM) Stress Test in the Diagnosis and Management of Coronary Heart Disease Validated in a new Study

BSP's HyperQ(TM) Test Reduces Radioactive and Costly Imaging by 13%, Healthcare Savings Exceeding $ US 1B Annually in the United States Alone

Jun 07, 2010, 04:18 ET from BSP - Biological Signal Processing Ltd

TEL AVIV, Israel, June 7, 2010 /PRNewswire-FirstCall/ -- BSP Biological Signal Processing Ltd. (http://www.bsp.co.il), develops and markets innovative systems for non-invasive diagnosis and monitoring of Ischemic Heart Disease (IHD) based on its proprietary HyperQ(TM) technology. BSP recently presented the results of a study on the economic and clinical benefits of the HyperQ(TM) stress test in the diagnosis and management of coronary heart disease (CHD) at the International Congress on Electrocardiology on June 4th, 2010.

Analysis of the patient workup for the diagnosis of CHD demonstrated that the improved clinical accuracy of the HyperQ(TM) compared to standard stress testing can potentially lead to a reduction of 13% in unnecessary cardiac imaging tests (750,000 tests annually in the USA), and a significant reduction in unwarranted angiographies (over 200,000 procedures annually in the USA) with healthcare savings exceeding $ 1 billion annually.

In addition, analysis of CHD patient care costs demonstrated that the use of HyperQ(TM) stress test reduces the number of undiagnosed patients and thus leads to an improvement in cardiac care and the accuracy of diagnosing CHD patients. Based on published data, routine use of the HyperQ(TM) will reduce the number of acute cardiac events (including heart attacks), and lower mortality resulting from CHD while reducing the overall costs to the health care system.

BSP intends to use this analysis' results in discussions with US insurers, aimed at allocating an elevated coverage code for the HyperQ(TM) procedure. HyperQ(TM) technology and the great economic benefit it offers correlate perfectly with the current administration's healthcare reform, supporting more cost-effective care and reducing unwarranted expensive and radioactive procedures.

About BSP

Founded in 2000, BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of cardiovascular disease. BSP's proprietary HyperQ(TM) technology is implemented in cardiac systems that offer accurate, low-cost and risk free cardiac monitoring and allows, for the first time, an effective diagnosis of ischemic heart disease in broad populations. BSP is a traded company on the Tel Aviv Stock Exchange since 2006 (TASE: BSP). The company's international offices are located in Tel Aviv, Israel and Rockville, Maryland, USA.

    For more information please contact:
    Dr. Amir Beker, CEO, Biological Signal Processing Ltd.
    amir@bspmedical.com
    Tel. +972-3-6474840

SOURCE BSP - Biological Signal Processing Ltd